Metastatic Cancer Clinical Trial
Official title:
Phase I/II Study of Adoptive Immunotherapy Comprising Pyrophosphomonoester Antigen-stimulated T Cells, IL-2, and Nitrogen-containing Bisphosphonates in Patients With Stage IV Renal Cell Carcinoma
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are
treated in the laboratory to stimulate the immune system in different ways and stop tumor
cells from growing. Aldesleukin may help the laboratory-treated white blood cells stay in
the body longer. Drugs used in chemotherapy, such as zoledronic acid, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving cellular adoptive immunotherapy together with interleukin-2 and zoledronic
acid may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects of giving cellular adoptive
immunotherapy together with aldesleukin and zoledronic acid and to see how well it works in
treating patients with stage IV kidney cancer and lung metastases.
OBJECTIVES:
- Determine the safety of adoptive immunotherapy comprising
2-methyl-3-butenyl-1-pyrophosphate-stimulated gamma delta (gd) T cells, zoledronate,
and IL-2 after nephrectomy, especially with regard to the incidence and frequency of
adverse events.
- Determine the duration of in vivo persistence of the transferred gd T cells in
patients.
- Determine the doubling time of tumor growth before and after adoptive immunotherapy.
- Determine the tumor-size reducing effect of adoptive immunotherapy based on the Best
Overall Response Chart.
OUTLINE: Patients undergo leukapheresis for the harvest of peripheral blood mononuclear
cells (PBMCs). PBMCs are stimulated with 2-methyl-3-butenyl-1-pyrophosphate and aldesleukin
for 11 days. Patients then receive the expanded Gamma Delta T cells, aldesleukin, and
zoledronic acid once a month for 6 months.
After completion of study treatment, patients are followed for up to 1 month.
;
Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT00005030 -
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
|
Phase 1 | |
| Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
| Recruiting |
NCT04085029 -
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
|
||
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05981170 -
Rurality Adapted Physical Activity Sport Health
|
||
| Not yet recruiting |
NCT03058809 -
Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood
|
Phase 1/Phase 2 | |
| Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT01302808 -
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
Phase 1 | |
| Terminated |
NCT00918645 -
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
|
N/A | |
| Withdrawn |
NCT00769990 -
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
|
Phase 1/Phase 2 | |
| Completed |
NCT00795678 -
Chemotherapeutic Agents in Brain/Breast
|
N/A | |
| Completed |
NCT00557102 -
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
|
Phase 2 | |
| Recruiting |
NCT00398437 -
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
|
N/A |